Recombinant VWF Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current plasma-derived VWF formulations face challenges with quantity and purity issues, as well as risks of blood-borne pathogens such as viruses and Variant Creutzfeldt-Jakob disease, necessitating the development of a stable recombinant VWF pharmaceutical composition.
Innovation Solution
A stable liquid pharmaceutical formulation of recombinant von Willebrand Factor (rVWF) is developed, comprising rVWF, a buffering agent, salts, optionally a stabilizing agent, and a surfactant, with specific concentrations and pH ranges to ensure stability and safety, using the amino acid sequence set out in SEQ ID NO: 3 and buffering agents like citrate and histidine, with salts such as calcium chloride and sodium chloride, and stabilizing agents like trehalose and mannitol.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If plasma-derived VWF formulations are used, then VWF can be obtained for therapeutic use, but there are risks of blood-borne pathogens and issues with quantity and purity
Solution Approach 1:
The patent extracts only the necessary VWF protein from plasma through purification processes, separating it from harmful blood-borne pathogens. This extraction principle allows obtaining therapeutic VWF while eliminating contaminants, resolving the contradiction between obtaining VWF and avoiding pathogens.
Solution Approach 2:
The patent creates a recombinant copy of VWF produced in cell cultures rather than using plasma-derived VWF. This copying approach generates identical therapeutic protein without the risks associated with human plasma, eliminating pathogen transmission while maintaining therapeutic efficacy.
2Quantity of substance
If plasma-derived VWF is used, then VWF therapy can be provided, but quantity and purity issues arise
Solution Approach 1:
The recombinant VWF production system creates unlimited copies of the VWF protein in cell cultures, overcoming the limited quantity available from plasma sources. This copying mechanism enables scalable production with consistent purity levels.
Solution Approach 2:
The patent employs multiple purification steps to extract and isolate VWF from complex cell culture media, achieving high purity levels. This extraction process removes contaminants while concentrating the therapeutic protein, resolving the purity challenge.
3Stability of the object's composition
If recombinant VWF formulation is developed, then stability and safety are improved, but formulation complexity increases
Solution Approach 1:
The patent optimizes formulation parameters such as pH, ionic strength, and excipient concentrations to achieve optimal stability of rVWF. By carefully adjusting these parameters, the formulation maintains protein stability without requiring overly complex composition.
Solution Approach 2:
The patent introduces excipients as intermediary substances that mediate between the rVWF protein and the formulation environment. These excipients protect the protein from degradation while maintaining solubility and stability, simplifying the overall formulation approach.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides long-term stable pharmaceutical formulations of recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.